

Longjumeau, 24 January 2013

Net sales up 5.9% in 2012

<i>(in thousands of euros)</i>	2010	2011	2012	% change
Total as of 31 December	158 511	164 544	174 289	5,9%
<i>including Pharmaceutical Synthesis</i>	<i>99 379</i>	<i>102 096</i>	<i>110 001</i>	<i>7,7%</i>
<i>including Fine Speciality Chemicals</i>	<i>59 132</i>	<i>62 448</i>	<i>64 288</i>	<i>2,9%</i>

The PCAS Group achieved 5.9% growth in consolidated net sales for 2012 compared with 2011.

Pharmaceutical Synthesis

Net sales are up 7.7% for 2012 compared with 2011, driven by activities based on proprietary technological platforms.

Fine Specialty Chemicals

The Fine Specialty Chemicals business has continued to grow (+2.9% in 2012 versus 2011), despite confirmation of the Fragrance business underperforming.

In view of this increase in sales, it is possible, as of now, to confirm a significant growth in current operating income for 2012 in relation to 2011.

Next date: 2012 results on 20 February 2013

About PCAS :

Founded in 1962, PCAS is an international fine and specialty chemicals group that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability. PCAS also develops ranges of proprietary products based on intellectual property.

